

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BioDlink International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1875)

(1) RESIGNATION OF DIRECTORS AND CHAIRPERSON OF THE BOARD; (2) APPOINTMENTS OF DIRECTORS, CHAIRPERSON OF THE BOARD AND CHANGES IN COMPOSITION OF BOARD COMMITTEES; AND (3) CHANGE OF AUTHORISED REPRESENTATIVE

RESIGNATION OF DIRECTORS AND CHAIRPERSON OF THE BOARD

The board of directors (the “**Board**”) of BioDlink International Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following change of directors (the “**Directors**”) and chief executive of the Company with effect from 29 April 2026:

- (i) Mr. Shan FU has resigned as an executive Director, the chairperson of the Board and a member and the chairperson of the Nomination Committee and the Strategy and ESG Committee of the Company;
- (ii) Dr. Weidong LIU has resigned as a non-executive Director, a member of the Audit and Connected Transactions Review Committee and the Strategy and ESG Committee of the Company;
- (iii) Ms. Hui SUN has resigned as an independent non-executive Director and a member and chairperson of the Audit and Connected Transactions Review Committee and a member of the Nomination Committee of the Company;
- (iv) Mr. Qing ZHANG has resigned as an independent non-executive Director and a member of the Audit and Connected Transactions Review Committee and a member and the chairperson of the Remuneration Committee of the Company; and
- (v) Dr. Xuelin GU has resigned as an independent non-executive Director and a member of the Remuneration Committee, the Nomination Committee and the Strategy and ESG Committee of the Company.

The resignation of the resigning Directors was in connection with the change in control of the Company after completion of the voluntary general cash offers and Wuxi XDC Cayman Inc. (藥明合聯生物技術有限公司*, HKEX: 2268) (“**WuXi XDC**”) became the controlling shareholder of the Company. For further details of the voluntary general cash offers, please refer to the joint announcement of Wuxi XDC and the Company dated 31 March 2026. Each of the resigning Directors has confirmed that he/she has no disagreement with the Board and there are no matters relating to his/her resignation which need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company.

The Board would like to express its gratitude to the resigning Directors for their contributions to the Company during their terms of service.

APPOINTMENTS OF DIRECTORS AND CHAIRPERSON OF THE BOARD

The Board is also pleased to announce that with effect from 29 April 2026:

- (i) Dr. Jincal LI (“**Dr. Li**”) has been appointed as an executive Director, the chairperson of the Board and the chairperson of each of the Nomination Committee and the Strategy and ESG Committee and member of the Remuneration Committee;
- (ii) Mr. Xiaojie XI (“**Mr. Xi**”) has been appointed as a non-executive Director and member of each of the Audit and Connected Transactions Review Committee and the Strategy and ESG Committee of the Company;
- (iii) Mr. Xin FAN (“**Mr. Fan**”) has been appointed as an independent non-executive Director and the chairperson of the Audit and Connected Transactions Review Committee and member of the Remuneration Committee of the Company;
- (iv) Dr. Ulf GRAWUNDER (“**Dr. Grawunder**”) has been appointed as an independent non-executive Director and the chairperson of the Remuneration Committee and member of each of the Nomination Committee and the Strategy and ESG Committee of the Company; and
- (v) Dr. Chaohong Hu (“**Dr. Hu**”) has been appointed as an independent non-executive Director and a member of each of the Audit and Connected Transactions Review Committee and the Nomination Committee of the Company.

The brief biographical details of the above appointed directors (the “**New Directors**”) are set out below.

Dr. Jincal LI (李錦才)

Dr. Li, aged 53, is an executive Director and chairman of the Board. He is primarily responsible for formulating overall strategic plans, business development and daily operations of the Group. Dr. Li has over 20 years of experience in biologics process development, scale-up and cGMP manufacturing (current good manufacturing practice). He has been a director of WuXi XDC since its incorporation in December 2020, and has been re-designated as an executive director and appointed as the chief executive officer of WuXi XDC since June 2023. Under his leadership, WuXi XDC became a leading antibody drug conjugate (“**ADC**”) and bioconjugates contract research, development and manufacturing organization (“**CRDMO**”), which was recognised by the 2022 World ADC Awards’ Runner Up prize in the “Best CMO Provider” category and the winner of the 2023 World ADC Awards’ prize in the “Best Contract Development Manufacturing Organization (CDMO)” category.

Dr. Li joined WuXi Biologics (Cayman) Inc. (together with its subsidiaries, “**WXB Group**”) in September 2011 and has served as the senior vice president at the WXB Group since May 2020. Before Dr. Li joined the WXB Group, from August 2007 to September 2011, Dr. Li had served as a group leader at Genentech, Inc. where he was responsible for cell culture process development. From April 2006 to July 2007, Dr. Li was a scientist at Tanox, Inc., and from August 2001 to March 2006, Dr. Li was a staff scientist at Diversa Corporation (now BASF) where he was in charge of process development for multiple biologics projects.

Dr. Li obtained a bachelor’s degree in chemical engineering and technology and minor in chemistry from Tsinghua University in the People’s Republic of China (the “**PRC**”) in July 1996. Dr. Li then obtained a doctoral degree majoring in chemical and biochemical engineering from University of Maryland Baltimore County in the United States in August 2001.

Mr. Xiaojie XI (席曉捷)

Mr. Xi, aged 50, is a non-executive Director. Mr. Xi is primarily responsible for overseeing the overall financial management, financial matters and strategic development of the Group. Mr. Xi has been an executive director of WuXi XDC since June 2023 and the chief financial officer and company secretary of WuXi XDC since May 2023 and November 2023, respectively. He brings over 20 years of financial industry experience in the United States and the PRC, including investment banking and private equity investment with many public and private companies.

Prior to joining WuXi XDC, from November 2018 to May 2023, Mr. Xi had served as the chief financial officer and simultaneously from April 2020 to May 2023, a joint company secretary of Akeso, Inc. (HKEX: 09926). Before that, from August 2017 to October 2018, he was a director at SIN Capital (HK) Limited, focusing on investments in the healthcare industry in China, and from April 2015 to July 2017, he served as a director of corporate finance and capital markets at CLSA Limited. Between October 2013 and April 2015, Mr. Xi was the vice president of investment banking and strategic advisory department at Credit Suisse AG

(Hong Kong branch). From March 2010 to April 2013, Mr. Xi served as the vice president of investment banking division at Morgan Stanley Asia Limited. During his time with the aforementioned investment banks, Mr. Xi had executed high profile transactions, including IPOs, debt and equity financings and M&As for leading companies in China.

Mr. Xi obtained his bachelor's degree in biochemistry from Wuhan University in the PRC in 1997 and obtained his master's degree in science from Rutgers, The State University of New Jersey in the United States in 2002. He then completed his Master's degree in business administration with distinction at New York University, Stern School of Business in the United States in 2008.

Mr. Xin FAN (樊欣)

Mr. Fan, aged 47, is an independent non-executive Director. Mr. Fan is primarily responsible for supervising and providing independent judgment to the board of the Group. Mr. Fan has served as the chief financial officer of Bilibili Inc. (哔哩哔哩股份有限公司) (Nasdaq: BILI; HKEX: 9626) since September 2017. Prior to that, Mr. Fan had served as Bilibili Inc.'s vice president of finance since April 2016. Before joining Bilibili Inc., Mr. Fan served as a finance director at NetEase, Inc. (網易股份有限公司) (Nasdaq: NTES; HKEX: 9999) from 2011 to 2016. Prior to 2011, Mr. Fan held various positions at KPMG Huazhen LLP (畢馬威華振會計師事務所(特殊普通合伙)) for an aggregate of eight years and served as a senior manager there from 2008 to 2011. Mr. Fan has also served as an independent director of Sipai Health Technology Co., Ltd. (思派健康科技有限公司) (HKEX: 0314) since May 2023 and as an independent director of MicroPort NeuroScientific Corporation (微創腦科學有限公司) (HKEX: 2172) since June 2024.

Mr. Fan received his bachelor's degree in international accounting from Shanghai University of Finance and Economics in the PRC in 2001. Mr. Fan is a regular member of the American Institute of Certified Public Accountants and a certified public accountant in the PRC. He also holds licences as chartered global management accountant and chartered certified accountant in the United Kingdom.

Dr. Ulf GRAWUNDER

Dr. Grawunder, aged 61, is an independent non-executive Director. He is primarily responsible for supervising and providing independent judgment to the board of the Group. Dr. Grawunder is an experienced Swiss life-science entrepreneur with over 20 years of experience in the therapeutic antibody development industry. He has also been an independent non-executive director of WuXi XDC since November 2023 and Nasdaq-listed Adagene Inc. (ADAG), since April 2024.

Dr. Grawunder is a co-founder and, since 2022, has served as chief executive officer and initially Board member of T-CURX LLC in Germany, a German biotech company that focuses on the development of next-generation CAR-T cell therapies for cancer patients. Furthermore, since 2022, he is also managing partner of Viopas Venture Consulting LLC, Switzerland. Before that, from 2012 to 2021, Dr. Grawunder was the founder and chief executive officer of NBE-Therapeutics Ltd in Switzerland, a biotech company developing ADCs for cancer therapy, acquired by Boehringer Ingelheim, Germany in 2021. Dr. Grawunder began his

industry career in 2003 by co-founding Swiss biotechnology company 4-Antibody Ltd, developing therapeutic antibodies in autoimmunity and oncology, where from 2006 to 2012 he initially served as chief executive officer and later as the chief scientific officer, until the company was sold to US-based, Nasdaq-listed Agenus Inc. (AGEN).

Dr. Grawunder served as advisor to Swiss ADC biotech company, Araris Biotech, until its acquisition by Japanese pharmaceutical company Taiho Pharmaceutical in March 2025. Since 2026 Dr. Grawunder is advisor to Swiss ADC biotech company Clearidebio-Therapeutics. From 2010 to 2014 Dr. Grawunder was also Vice-president of the Swiss Biotech Association.

Dr. Grawunder obtained his bachelor's degree in biochemistry in October 1988 and his master's degree in biochemistry in July 1991, both from the University of Bayreuth, Germany. He subsequently obtained his doctoral degree in cell biology from the University of Basel in Switzerland in July 1994, followed by post-doctoral research in the U.S. at Washington University School of Medicine in St. Louis, MO, and University of Southern California in Los Angeles, CA, from 1995-1998. In addition, Dr. Grawunder holds a diploma in Technology Entrepreneurship from the University St. Gallen, School of Business, in Switzerland.

Dr. Chaohong HU (胡朝紅)

Dr. Hu, aged 60, is an independent non-executive Director. Dr. Hu is primarily responsible for supervising and providing independent judgment to the board of the Group. She has been an independent non-executive director of Hutchmed (China) Limited (和黃醫藥(中國)有限公司) (HKEX: 0013) since 2024 and is currently the chief operating officer of D Biotherapeutics, LLC and an owner and principal consultant of Lakebio Consulting, LLC. She was previously the executive director and co-chief executive officer of Lepu Biopharma Co., Ltd. (樂普生物科技股份有限公司) (HKEX: 2157) from 2020 to January 2024. She was also chief executive officer and chairman of the board of Shanghai Miracogen Inc. (上海美雅珂生物技術有限責任公司) (“**Shanghai Miracogen**”), a company founded by Dr. Hu, focusing on the research and development, clinical study and industrialization of new drugs for targeted cancer therapy – ADCs, from 2014 to January 2024. She disposed of all her interests in Shanghai Miracogen in 2020. Prior to founding Shanghai Miracogen, Dr. Hu served as a director of the Bioassay Development and Process Analytics department at Seagen Inc. (previously listed on Nasdaq); director of the Molecular Biology and Clinical Immunology department of GlaxoSmithKline plc (currently GSK plc) (葛蘭素史克股份有限公司) (LSE/NYSE: GSK); and research scientist and director of the Molecular Biology and Clinical Immunology department of ID Biomedical Corporation (previously listed on Nasdaq). She was also a post-doctoral fellow of the University of Washington.

Dr. Hu holds a Bachelor of Science degree in biochemistry from Wuhan University in the PRC and a PhD in molecular biology from Institute of Biophysics, Chinese Academy of Sciences in the PRC.

Dr. Li has entered into a service contract with the Company, and each of Mr. Xi, Mr. Fan, Dr. Grawunder and Dr. Hu has entered into a director's appointment letter with the Company, in each case, for a term of three years which is terminable by either party with one month's written notice. All the New Directors are subject to retirement by rotation and re-election at least once every three years at annual general meetings of the Company in accordance with the articles of association of the Company and the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

Dr. Li and Mr. Xi will not receive additional remuneration from the Company serving as Directors, while Each of Mr. Fan, Dr. Grawunder and Dr. Hu is entitled to director's fee of HK\$450,000. The emoluments of each of the New Directors were determined by the remuneration committee of the Company with reference to his or her qualification and experience and his or her duties and responsibilities within the Company, the terms of the remuneration policy of the Company and the recommendation from the remuneration committee.

Save as disclosed in this announcement, as at the date of this announcement:

- (i) each of the New Directors has not held any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas for the last three years preceding the date of his/her appointment or had other major appointments or professional qualifications;
- (ii) each of the New Directors does not have, or is not deemed to have, any interest in the Shares (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong));
- (iii) each of the New Directors does not have any other relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (as respectively defined in the Listing Rules) of the Company;
- (iv) each of the New Directors does not hold any other position in the Company or other members of the Group; and
- (v) there is no other information relating to the New Directors that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules or any matters that need to be brought to the attention of the Shareholders in relation to his or her appointment.

Save as disclosed above, each of Mr. Fan, Dr. Grawunder and Dr. Hu has confirmed (a) his/her independence as regards each of the factors for independence referred to in Rule 3.13(1) to (8) of the Listing Rules; (b) that he/she had no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (c) that there are no other factors that may affect his/her independence at the time of his/her appointment.

The Board would like to take this opportunity to extend its warmest welcome to the New Directors for joining the Board.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board announces that with effect from the date of this announcement, the respective composition of the board committees is as follows:

Audit and Connected Transactions Review Committee

Mr. Fan has been appointed as the chairperson of the Audit and Connected Transactions Review Committee, and Mr. Xi and Dr. Hu have each been appointed as members of the Audit and Connected Transactions Review Committee. The Audit and Connected Transactions Review Committee comprises Mr. Fan (as chairperson), Mr. Xi and Dr. Hu.

Remuneration Committee

Dr. Grawunder has been appointed as the chairperson of the Remuneration Committee, and Dr. Li and Mr. Fan have each been appointed as members of the Remuneration Committee. The Remuneration Committee comprises Dr. Grawunder (as chairperson), Dr. Li and Mr. Fan.

Nomination Committee

Dr. Li has been appointed as the chairperson of the Nomination Committee, and Dr. Grawunder and Dr. Hu have each been appointed as members of the Nomination Committee. The Nomination Committee comprises Dr. Li (as chairperson), Dr. Grawunder and Dr. Hu.

Strategy and ESG Committee

Dr. Li has been appointed as the chairperson of the Strategy and ESG Committee, and Mr. Xi and Dr. Grawunder have each been appointed as members of the Strategy and ESG Committee. The Strategy and ESG Committee comprises Dr. Li (as chairperson), Mr. Xi and Dr. Grawunder.

CHANGE OF AUTHORISED REPRESENTATIVE

Following the cessation of directorship of Mr. Shan FU, Mr. Xi has been appointed as an authorised representative of the Company as required under Rule 3.05 of the Listing Rules in replacement of Mr. Shan FU with effect from the date of this announcement. The authorised representatives of the Company are Mr. Xi and Mr. Lui, Wing Yat Christopher.

COMPLIANCE WITH RULE 3.10A OF THE LISTING RULES

Following the resignation of the resigning Directors and the appointment of the New Directors, the Board comprises five members, of which one is executive Director, one is non-executive Director and three are independent non-executive Directors. As such, the Company is in compliance with the requirement of having independent non-executive directors representing at least one-third of the Board under Rule 3.10A of the Listing Rules.

By order of the Board of
BioDlink International Company Limited
Mr. Fu, Shan
Executive Director

Hong Kong, 28 April 2026

As at the date of this announcement, the executive director of the Company is Mr. Fu, Shan; the non-executive director of the Company is Dr. Liu, Weidong; and the independent non-executive directors of the Company are Ms. Sun, Hui, Mr. Zhang, Qing and Dr. Gu, Xuelin.